Knight Therapeutics Stock Performance
| GUD Stock | CAD 6.00 0.05 0.83% |
Knight Therapeutics has a performance score of 4 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.0904, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Knight Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Knight Therapeutics is expected to be smaller as well. Knight Therapeutics right now secures a risk of 1.36%. Please verify Knight Therapeutics information ratio, value at risk, kurtosis, as well as the relationship between the sortino ratio and semi variance , to decide if Knight Therapeutics will be following its current price movements.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Knight Therapeutics are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very healthy fundamental indicators, Knight Therapeutics is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | 17 M |
Knight |
Knight Therapeutics Relative Risk vs. Return Landscape
If you would invest 577.00 in Knight Therapeutics on April 23, 2025 and sell it today you would earn a total of 23.00 from holding Knight Therapeutics or generate 3.99% return on investment over 90 days. Knight Therapeutics is generating 0.0723% of daily returns assuming 1.3643% volatility of returns over the 90 days investment horizon. Simply put, 12% of all stocks have less volatile historical return distribution than Knight Therapeutics, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Knight Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Knight Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Knight Therapeutics, and traders can use it to determine the average amount a Knight Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.053
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | GUD | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.36 actual daily | 12 88% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Knight Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Knight Therapeutics by adding it to a well-diversified portfolio.
Knight Therapeutics Fundamentals Growth
Knight Stock prices reflect investors' perceptions of the future prospects and financial health of Knight Therapeutics, and Knight Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Knight Stock performance.
| Return On Equity | 0.0142 | ||||
| Return On Asset | -5.0E-4 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 475.81 M | ||||
| Shares Outstanding | 99.63 M | ||||
| Price To Earning | 133.90 X | ||||
| Price To Book | 0.76 X | ||||
| Price To Sales | 1.62 X | ||||
| Revenue | 371.3 M | ||||
| EBITDA | 46.76 M | ||||
| Cash And Equivalents | 5.11 M | ||||
| Cash Per Share | 4.10 X | ||||
| Total Debt | 168.69 M | ||||
| Debt To Equity | 0.06 % | ||||
| Book Value Per Share | 8.00 X | ||||
| Cash Flow From Operations | 36.28 M | ||||
| Earnings Per Share | 0.10 X | ||||
| Total Asset | 963.8 M | ||||
| Retained Earnings | 154.91 M | ||||
| Current Asset | 499.48 M | ||||
| Current Liabilities | 6.74 M | ||||
About Knight Therapeutics Performance
By examining Knight Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Knight Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Knight Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company was incorporated in 2013 and is headquartered in Montreal, Canada. KNIGHT THERAPEUTICS operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange.Things to note about Knight Therapeutics performance evaluation
Checking the ongoing alerts about Knight Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Knight Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 46.0% of the company shares are held by company insiders |
- Analyzing Knight Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Knight Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Knight Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Knight Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Knight Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Knight Therapeutics' stock. These opinions can provide insight into Knight Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Knight Stock
Knight Therapeutics financial ratios help investors to determine whether Knight Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Knight with respect to the benefits of owning Knight Therapeutics security.